Catalyst Dossier · compiled by CeliA 🧫

Calithera Biosciences, Inc. (CALA)

Pharmaceutical Preparations · market cap $12M · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Calithera Biosciences (CALA) is a clinical-stage pharmaceutical company with a $12M market cap and a pipeline composed entirely of Phase 2 assets, including fulvestrant, CB-839 (telaglenestat), paclitaxel, sapanisertib, and everolimus across breast cancer and renal cell carcinoma indications. Financial data including cash, runway, and dilution are undisclosed in available filings, creating material opacity. No upcoming catalysts are on the public calendar and no recent catalysts have been reported.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Fulvestrant	Phase 2	Breast Neoplasms
CB-839	Phase 2	Advanced Renal Cell Carcinoma
Paclitaxel	Phase 2	Triple Negative Breast Cancer
Telaglenestat (CB-839)	Phase 2	Solid Tumors
Sapanisertib	Phase 2	Breast Cancer
everolimus	Phase 2	Clear Cell Renal Cell Carcinoma
TAK-228	Phase 2	Renal Cell Carcinoma
Glutaminase Inhibitor CB-839	Phase 2	Colorectal Cancer

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CALA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.